Get the Stockscreener App
7.99
0.13%
0.010
After Hours:
7.99
Eyepoint Pharmaceuticals Inc stock is traded at $7.99, with a volume of 320.98K.
It is up +0.13% in the last 24 hours and down -10.73% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$7.98
Open:
$7.94
24h Volume:
320.98K
Relative Volume:
0.47
Market Cap:
$430.82M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-2.8333
EPS:
-2.82
Net Cash Flow:
$-1.61M
1W Performance:
-3.62%
1M Performance:
-10.73%
6M Performance:
-61.34%
1Y Performance:
+0.00%
1-Day Range:
$7.93
$8.40
1-Week Range:
$7.90
$8.58
52-Week Range:
$5.67
$30.99
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
(EYPT) Long Term Investment Analysis - Stock Traders Daily
Canada Pension Plan Investment Board Sells 114,400 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] Sees Decrease in Stock Value - Knox Daily
Deerfield Management Company L.P. Series C Has $7.64 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals Inc (EYPT)’s Day in Review: Closing at 8.34, Up by 0.60 - The Dwinnex
Are EyePoint Pharmaceuticals Inc (EYPT) shares a good deal now? - US Post News
Diabetic Macular Edema Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharma, RemeGen - Barchart
EyePoint Pharmaceuticals Inc (EYPT) receives a Buy rating from Jefferies - Knox Daily
StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to Sell - MarketBeat
Federated Hermes Inc. Decreases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
Post-Trade Analysis: EyePoint Pharmaceuticals Inc (EYPT) Climbs 3.03, Closing at 9.18 - The Dwinnex
Insider Buying: DICICCO WENDY F, EyePoint Pharmaceuticals Inc [EYPT] Director invested 2,567 shares - Knox Daily
EyePoint Pharmaceuticals Inc (EYPT)’s stock price range in the last year - US Post News
Learn to Evaluate (EYPT) using the Charts - Stock Traders Daily
An Analysis of EyePoint Pharmaceuticals Inc (EYPT)’s Potential Price Growth - Knox Daily
Stocks of EyePoint Pharmaceuticals Inc (EYPT) are poised to climb above their peers - SETE News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.6% Higher - MarketBeat
Investing in EyePoint Pharmaceuticals Inc (EYPT): What You Must Know - Knox Daily
An analyst sees good growth prospects for EyePoint Pharmaceuticals Inc (EYPT) - SETE News
EyePoint Pharmaceuticals Inc (EYPT) did well last session? - US Post News
The Escalator: MM+M, Dyne Therapeutics, EyePoint Pharmaceuticals and more - MM+M Online
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Upgraded by StockNews.com - MarketBeat
EyePoint Pharmaceuticals adds industry veteran to board - Investing.com India
EyePoint Pharmaceuticals Appoints Fred Hassan to Board of Directors - citybiz
EyePoint Pharmaceuticals Announces Board Changes and New Appointments - TipRanks
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors - StockTitan
(EYPT) Trading Signals - Stock Traders Daily
EyePoint Pharmaceuticals Inc [EYPT] Investment Guide: What You Need to Know - Knox Daily
EYPT’s Stock Dilemma: EyePoint Pharmaceuticals Inc’s Market Performance and Outlook - The InvestChronicle
Panagora Asset Management Inc. Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade) - Seeking Alpha
EyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at Jefferies Financial Group - Defense World
Jefferies Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy Recommendation - MSN
Jefferies starts EyePoint Pharmaceuticals stock with Buy, reflecting over 65% upside potential - Investing.com Australia
Jefferies starts EyePoint Pharmaceuticals stock with Buy, reflecting over 65% upside potential - Investing.com Canada
Jefferies Financial Group Begins Coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) - MarketBeat
Jefferies starts EyePoint Pharmaceuticals stock with Buy, reflecting over 65% upside potential - Investing.com India
Jefferies starts EyePoint Pharmaceuticals stock with Buy, reflecting over 65% upside potential - Investing.com UK
Legato Capital Management LLC Sells 52,297 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - StockTitan
Analyzing EyePoint Pharmaceuticals Inc (EYPT) After Recent Trading Activity - Knox Daily
EyePoint Pharmaceuticals director buys $99,750 in company stock - Investing.com India
EyePoint Pharmaceuticals director buys $39,750 in stock - Investing.com India
EyePoint Pharmaceuticals director buys $99,750 in company stock By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals Inc (EYPT) deserves closer scrutiny - US Post News
EyePoint Pharmaceuticals director buys $39,750 in stock - Investing.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Director Acquires $19,996.93 in Stock - MarketBeat
Taking a Closer Look At EyePoint Pharmaceuticals Inc (EYPT) Following Its Recent Trade - Knox Daily
EyePoint Pharmaceuticals director buys $99,750 in company stock By Investing.com - Investing.com UK
Trading Day Triumph: EyePoint Pharmaceuticals Inc (EYPT) Ends at 7.72, a -2.77 Surge/Plunge - The Dwinnex
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):